NasdaqGS:ZYMEBiotechs
ZW191’s Broad Phase 1 Activity in Ovarian Cancer Could Be A Game Changer For Zymeworks (ZYME)
Zymeworks recently reported Phase 1 data for its folate receptor alpha-targeting ADC ZW191, showing meaningful anti-tumor activity and a manageable safety profile in platinum-resistant ovarian and endometrial cancer patients across both FRa-positive and FRa-negative tumors.
The breadth of responses regardless of FRa expression level suggests ZW191 could potentially widen the use of FRa-directed therapies beyond the narrow biomarker-defined populations targeted by current options.
We’ll now...